- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02010294
Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections (StreptoPedia)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The group A streptococcus (GAS) or Streptococcus pyogenes is a strictly human pathogen , which can cause a wide variety of infections. These range from a simple asymptomatic carriage up to 20 % of children , or minor illnesses such as sore throat or impetigo, to severe conditions such as necrotizing fasciitis and toxic shock syndrome .
The pathophysiological mechanisms of invasive GAS infections are poorly understood. These mechanisms could involve not only virulence factors of the bacterium ( M protein determines the emm genotype , but also super- antigenic exotoxins SpeA , Spe C, Ssa, Sme z or other virulence genes , SilC , ... Sic ), but also in some cases, factors associated with host immunity in particular in the absence of risk factors for invasive skin infection such as cutaneous effraction ( wound , burn , chicken pox ) , corticosteroids or other immunosuppressive therapy and recent surgery .
The investigators assume that in some invasive GAS infections, especially in children without risk factors, Mendelian susceptibility to infection may be involved . This hypothesis could be tested by studying the molecular characteristics of strains isolated SGA and innate and adaptive immunity in children hospitalised for invasive GAS infection with or without identified risk factors for infection.
This study could not only lead to a better understanding of the pathophysiological mechanisms of invasive GAS infections but also to detect in children who underwent invasive GAS genetic susceptibility to infections requiring specific care . Finally, it could also identify specific strains of SGA or molecular profiles, whose detection in practice, lead to a suspicion of hereditary immune deficiency.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75019
- Robert Debre Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 1 month to <15 years at the time of inclusion
Group 1 : Children hospitalized for invasive GAS infection
- Subgroup 1A ( N = 75 ): Children with invasive infection without known risk factor .
- Subgroup 1B (N = 75) : Children with invasive infection with known risk factor .
GAS Invasive infections are defined by:
a) Proved infection : Bacteriological isolation of S. pyogenes from a liquid or a normally sterile site, except from a blister of a simple erysipelas, without necrosis . This is sometimes associated with a shock with multiorgan failure (streptococcal toxic shock syndrome ( STSS )) b ) Probable infection :
- . Bacteriological isolation of S. pyogenes from a normally non-sterile site ( eg skin, upper respiratory tract ) associated with extensive soft tissue necrosis
- . Bacteriological isolation of S. pyogenes a site or a biological sample usually non-sterile ( eg skin , upper respiratory tract ) associated with a evocative shock syndrome STSS and no other cause found .
Contributing factors for invasive infection are defined by:
cutaneous effraction (wounds , burn , chicken pox ), the use of corticosteroids or other treatment, immunosuppressive and recent surgery
• Group 2: non-invasive infection such as pharyngitis , tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture.
Exclusion Criteria:
- Group 1: Children with a known immune deficiency unrelated to the risk factors described above.
- Group 2: Children with a known immune deficiency.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Children hospitalized for invasive GAS infection
|
DNA samples,GAS strains
|
Children with non-invasive infection
Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
|
DNA samples,GAS strains
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
virulence factors of GAS
Time Frame: up to 3 years
|
characterize the virulence factors of GAS
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the frequency and type of hereditary immune deficiency or Mendelian susceptibility to infections associated with invasive GAS infections in children without risk factors
Time Frame: up to 3 years
|
frequency and type of hereditary immune deficiency or Mendelian susceptibility to infections associated with invasive GAS infections
|
up to 3 years
|
describe and compare the GAS emm genotypes and virulence factors with the profiles of strains isolated with invasive GAS infection with known risk factors and with the profile of strains isolated with a non-invasive GAS infections
Time Frame: up to 3 years
|
describe and compare the GAS emm genotypes and virulence factors profile of GAS associated with an inherited immune deficiency, or a Mendelian susceptibility to infection, with the profiles of strains isolated in children with invasive GAS infection with known risk factors (use of steroids, varicella, wounds…) and with the profile of strains isolated in children with a non-invasive GAS infections
|
up to 3 years
|
compare GAS emm genotypes and profiles of virulence strains responsible for invasive SGA infections with strains causing noninvasive infections
Time Frame: up to 3 years
|
compare GAS emm genotypes and profiles of virulence strains responsible for invasive SGA infections with strains causing noninvasive infections
|
up to 3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Albert FAYE, MD, PhD, APHP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P120136
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive GAS Infection
-
Melbourne HealthMerck Sharp & Dohme LLCRecruitingFungal Infection | Pharmacokinetics | Invasive Aspergillosis | Prophylaxis | Invasive Candidiases | Posaconazole | Invasive MycosisAustralia
-
Radboud University Medical CenterCompletedInvasive Fungal InfectionNetherlands
-
People's Hospital of Zhengzhou UniversityCompletedAn Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDMInvasive Fungal InfectionChina
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Kirby InstituteNot yet recruitingInvasive Fungal Infections | Infection, Bacterial | Infection, Fungal | Injection Site Infection | Infection, Soft Tissue | Invasive Bacterial Infection
-
Daping Hospital and the Research Institute of Surgery...RecruitingInvasive Fungal Infection | Neonatal Infection | Plasma AdministrationChina
-
University of BolognaUnknownInvasive Candidiases | Abdominal InfectionItaly
-
Merck Sharp & Dohme LLCRecruitingInvasive Fungal InfectionIsrael, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
-
Mahidol UniversityCompleted
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUnknown
Clinical Trials on DNA samples, GAS strains
-
Akdeniz UniversityCompletedHyperoxia | Kidney Transplant; Complications | Graft DysfunctionTurkey
-
Weill Medical College of Cornell UniversityHamad Medical CorporationTerminatedSkeletal DysplasiaQatar
-
Sunnybrook Health Sciences CentreCompleted
-
Rigshospitalet, DenmarkCompleted
-
Assiut UniversityUnknownPrimary Immune Thrombocytopenia
-
IRCCS Eugenio MedeaMinistry of Health, ItalyCompletedA Multi-domain Approach for the Characterization and Early Diagnosis of Neurodevelopmental DisordersNeurodevelopmental DisordersItaly
-
Barzilai Medical CenterUnknownOral Squamous Cell Carcinoma | Medication Related Osteonecrosis of the Jaw | Oral Epithelial DysplasiaIsrael
-
University Hospital, ToulouseCompleted
-
Weill Medical College of Cornell UniversitySentire Medical SystemsRecruitingCrohn's Disease of Large Intestine | Malignant Neoplasm of ColonUnited States
-
University of ChicagoNational Institutes of Health (NIH); American Society of Clinical OncologyCompleted